研究概要
我们的研究结果提出了一个以CIK-EIG为锚点的转录组学和预后框架,并强调了TNFSF14在进一步优化ccRCC患者基于CIK的免疫治疗中的潜在相关性。
中文摘要
在过继性免疫细胞治疗中,细胞因子诱导的杀伤细胞(CIK)治疗已在多种癌症中显示出明确的治疗相关性,尤其是在透明细胞肾细胞癌(ccRCC)中。尽管在临床上取得了成功,但与这些CIK细胞在癌症中的免疫调节作用相关的分子特征仍然不清楚。鉴于此,我们系统地从其转录组图谱中鉴定了CIK扩增诱导基因(CIK-EIGs),并在bulk和单细胞ccRCC数据集中构建了以CIK-EIG为锚点的转录组框架。利用全面的生物信息学分析,我们接下来开发了以CIK-EIG为锚点的风险分层(CIKRRS),其能够可靠预测患者预后,与临床-病理进程相关,并定义了一种免疫炎症性但临床不利的表型。有趣的是,整合分析突出显示TNFSF14是CIK-EIG相关免疫景观中的关键功能调节因子之一,与细胞毒性免疫信号和癌症-免疫循环活性密切相关。随后,功能实验验证了TNFSF14显著增强了ccRCC细胞系中CIK介导的肿瘤细胞杀伤、脱颗粒和细胞因子产生,证实了其在增强CIK效应功能中的作用。综上所述,我们的研究结果提出了一个以CIK-EIG为锚点的转录组和预后框架,并突出了TNFSF14在进一步优化ccRCC患者基于CIK的免疫治疗中的潜在相关性。
展开英文摘要原文
Among adoptive immune cell therapies, cytokine-induced killer cell (CIK) therapy has demonstrated clear therapeutic relevance in multiple cancers, particularly clear cell renal cell carcinoma (ccRCC). Despite being clinically successful, the molecular signatures associated with the immune-regulatory role of these CIK cells in cancers remain elusive. Considering this, we systematically identified CIK expansion-induced genes (CIK-EIGs) from their transcriptome profiles and curated the CIK-EIG-anchored transcriptome framework across bulk and single-cell ccRCC datasets. Using comprehensive bioinformatics analysis, we next developed the CIK-EIG-anchored risk stratification (CIKRRS), which enabled reliable prediction of patient prognosis, correlated with the clinical-pathological course, and defined an immunologically inflamed but clinically unfavorable phenotype. Of interest, the integrative analyses highlighted TNFSF14 as one of the key functional modulators within the CIK-EIG-associated immune landscape, showing a strong association with cytotoxic immune signaling and cancer-immunity cycle activity. Subsequently, the functional assays verified that TNFSF14 significantly enhanced CIK-mediated tumor cell killing, degranulation, and cytokine production in ccRCC cell lines, confirming its role in enhancing CIK effector function. Taken together, our findings present a CIK-EIG-anchored transcriptomic and prognostic framework and highlight the potential relevance of TNFSF14 for further optimization of CIK-based immunotherapy in ccRCC patients.
论文信息
- 作者
- Chen Y、Chen L、Qin X、Li Y、Wu D、Setiawan MF、Lukacs-Kornek V、Ritter M
- 第一作者单位
- Department of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.Germany
- 通讯作者单位
- Department of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. ingo.schmidt-wolf@ukbonn.de.Germany
- 期刊
- Cancer immunology, immunotherapy : CII2026 May 20